GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin.
1/5 보강
In a large retrospective study, those taking a glucagon-like peptide 1 (GLP-1) receptor agonist drug were 36% less likely to develop colorectal cancer than those taking aspirin.
APA
(2026). GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin.. Cancer discovery, 16(3), OF1. https://doi.org/10.1158/2159-8290.CD-NW2026-0002
MLA
. "GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin.." Cancer discovery, vol. 16, no. 3, 2026, pp. OF1.
PMID
41543505 ↗
Abstract 한글 요약
In a large retrospective study, those taking a glucagon-like peptide 1 (GLP-1) receptor agonist drug were 36% less likely to develop colorectal cancer than those taking aspirin. Although the benefit seen for any one person was small, thousands could potentially see a benefit given the large number of people taking GLP-1s.d.